Published in Drug Week, July 4th, 2003
Key elements of the restructuring will include concentration of research and development operations into a single location, Cambridge, Massachusetts, a reduction in overall headcount from approximately 2,300 to approximately 1,700 by the end of 2004, and a greater focus within a more tightly defined portfolio of discovery and development projects.
"The recent approval and launch of Velcade (bortezomib) for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week